Display options
Share it on

Exp Ther Med. 2012 Sep;4(3):497-502. doi: 10.3892/etm.2012.625. Epub 2012 Jun 28.

Association of FAS gene polymorphisms with systemic lupus erythematosus: A case-control study and meta-analysis.

Experimental and therapeutic medicine

Man-Man Lu, Qian-Ling Ye, Chen-Chen Feng, Jie Yang, Tao Zhang, Jing Li, Rui-Xue Leng, Hai-Feng Pan, Hui Yuan, Dong-Qing Ye

Affiliations

  1. Department of Epidemiology and Biostatistics, School of Public Health, and ; Anhui Provincial Laboratory of Population Health and Major Disease Screening and Diagnosis, Anhui Medical University, Hefei, Anhui 230032;

PMID: 23181125 PMCID: PMC3503889 DOI: 10.3892/etm.2012.625

Abstract

The association of functional polymorphisms in the promoter of the apoptosis gene FAS with systemic lupus erythematosus (SLE) susceptibility has been a controversial subject. We conducted a case-control study to investigate this association in a Chinese population and performed a meta-analysis in different populations. The single nucleotide polymorphisms (SNPs) rs2234767 (-1377G>A) and rs1800682 (-670A>G) were genotyped by TaqMan allelic discrimination assays in 552 Chinese SLE patients and 718 healthy controls. In our case-control study, we observed allelic association between the promoter SNP rs2234767 [P=0.033, odds ratio (OR)=0.836, 95% confidence interval (CI), 0.709-0.986] and SLE but not the SNP rs1800682. Haplotype analysis revealed that one haplotype of GA was significantly associated with the disease (P=0.039, OR=1.184, 95% CI, 1.009-1.391). In the meta-analysis available studies, including our data, were combined using the STATA software package v.7.0. The meta-analysis revealed a significant association between FAS polymorphisms and SLE (rs2234767 A vs. G allele; P=0.004, OR=0.819, 95% CI, 0.715-0.938, rs1800682 G vs. A allele: P=0.034, OR=0.791, 95% CI, 0.637-0.983). In conclusion, FAS gene polymorphisms may contribute to SLE susceptibility in the Chinese population, and the meta-analysis shows that FAS polymorphisms may be associated with SLE susceptibility in different populations.

References

  1. Stat Med. 2002 Jun 15;21(11):1539-58 - PubMed
  2. Lupus. 1998;7(7):455-61 - PubMed
  3. Mol Immunol. 1997 Jun;34(8-9):577-82 - PubMed
  4. Immunol Invest. 2010;39(1):27-38 - PubMed
  5. J Immunol. 2001 Nov 15;167(10):5963-9 - PubMed
  6. Rheumatology (Oxford). 1999 Jul;38(7):645-51 - PubMed
  7. Cancer Res. 2003 Aug 1;63(15):4327-30 - PubMed
  8. J Rheumatol. 2002 Jun;29(6):1183-8 - PubMed
  9. Lab Invest. 1993 Oct;69(4):415-29 - PubMed
  10. Clin Exp Dermatol. 2012 Jun;37(4):425-7 - PubMed
  11. Arthritis Rheum. 2003 Oct;48(10):2888-97 - PubMed
  12. J Natl Cancer Inst. 1959 Apr;22(4):719-48 - PubMed
  13. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  14. J Biol Chem. 1995 Dec 22;270(51):30264-7 - PubMed
  15. J Rheumatol. 2001 Sep;28(9):2008-11 - PubMed
  16. J Immunol. 1994 Apr 1;152(7):3685-92 - PubMed
  17. Clin Immunol. 2004 Sep;112(3):210-8 - PubMed
  18. Pathology. 2000 May;32(2):126-30 - PubMed
  19. Cell Res. 2005 Feb;15(2):97-8 - PubMed
  20. Genomics. 1992 Nov;14(3):821-2 - PubMed
  21. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
  22. Lupus. 2001;10(12):866-72 - PubMed
  23. Arthritis Rheum. 1997 Sep;40(9):1725 - PubMed
  24. Rheum Dis Clin North Am. 2004 Aug;30(3):505-27, viii-ix - PubMed
  25. Semin Immunol. 2006 Aug;18(4):224-9 - PubMed
  26. Curr Rheumatol Rep. 2000 Feb;2(1):32-8 - PubMed

Publication Types